Stada Group
Dana Winkler has diverse work experience spanning various industries and roles. They have recently worked at STADA Group, starting in 2021 as a Business Manager and later transitioning to the position of Head of Sales Force Effectiveness. Prior to that, Dana worked at PwC Deutschland as a Senior Associate in Transactions, delivering deal value. They also served as an Associate and a Working Student in the same department. Additionally, Dana has experience as a Student Assistant at Goethe-Universität Frankfurt a. Main, an Intern at EY in the Advisory Services Performance Improvement team, a Strategic Planning Intern at FP7, and an IT Intern at Gulf Petrochemical Industries Co.
Dana Winkler has a Bachelor of Science (B.Sc.) degree in Business Administration and Economics from Goethe University Frankfurt, which they obtained from 2012 to 2015. Dana also pursued a Master of Science (MSc) degree in Betriebswirtschaftslehre - Managerial Economics & Information Management from Goethe University Frankfurt from 2015 to 2018. Dana participated in a semester abroad at Université Paris Dauphine - PSL in 2016-2017, focusing on Economics. Dana further enhanced their education by completing certifications including the Dean's List of Goethe-Universität Frankfurt, and achieving a TOEFL score of 114/120. Dana recently attended IMD, where they completed the Leadership Essentials program in 2021 and the Future Leaders program in 2022.
This person is not in the org chart
This person is not in any offices
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.